| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| P2093 | author name string | Nicholas P Restifo | |
| Paul F Robbins | |||
| Steven E Finkelstein | |||
| Jehad Charo | |||
| Navrose Grewal | |||
| P2860 | cites work | Cancer immunotherapy: moving beyond current vaccines | Q24548229 |
| IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells | Q24621753 | ||
| Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes | Q24676216 | ||
| bcl-2 proto-oncogene expression during human T cell development. Evidence for biphasic regulation | Q72817307 | ||
| T cell fitness determined by signal strength | Q73134915 | ||
| Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma | Q74535384 | ||
| Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity | Q77929305 | ||
| Expanding small RNA interference | Q78021693 | ||
| Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity | Q28138855 | ||
| Bcl-2 rescues T lymphopoiesis, but not B or NK cell development, in common gamma chain-deficient mice | Q28513706 | ||
| Role of Bcl-2 in alpha beta T cell development in mice deficient in the common cytokine receptor gamma-chain: the requirement for Bcl-2 differs depending on the TCR/MHC affinity | Q28585384 | ||
| Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death | Q33876302 | ||
| Caspases: more than just killers? | Q34207528 | ||
| Progress in human tumour immunology and immunotherapy | Q34253585 | ||
| Retroviruses as tools to study the immune system | Q34332713 | ||
| Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction | Q34354588 | ||
| Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells | Q34415738 | ||
| Lymphocyte apoptosis: refining the paths to perdition | Q34468213 | ||
| Homeostatic control of lymphocyte survival: potential origins and implications | Q34658353 | ||
| Dysregulation of apoptosis genes in hematopoietic malignancies. | Q34658574 | ||
| Role of Bcl-2 family of proteins in malignancy | Q34733047 | ||
| Gene silencing in mammals by small interfering RNAs | Q34931992 | ||
| Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more | Q34987905 | ||
| Targeting tumours with genetically enhanced T lymphocytes | Q35037678 | ||
| Positive and negative selection of T cells in T-cell receptor transgenic mice expressing a bcl-2 transgene | Q35045775 | ||
| Apoptosis in the development and maintenance of the immune system | Q35116684 | ||
| Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction | Q35142962 | ||
| Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. | Q36371632 | ||
| High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens | Q36471584 | ||
| Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma | Q36696205 | ||
| Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity | Q36726945 | ||
| Differential effects of Bcl-2 on T and B cells in transgenic mice | Q37321476 | ||
| Generation of high-titer pseudotyped retroviral vectors with very broad host range | Q40571115 | ||
| Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. | Q40616262 | ||
| Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense | Q40739621 | ||
| Cutting edge: increased expression of Bcl-2 in antigen-specific memory CD8+ T cells | Q42486244 | ||
| Applications of the polymerase chain reaction in retroviral-mediated gene transfer and the analysis of gene-marked human TIL cells | Q44942700 | ||
| A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency | Q45857796 | ||
| Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions | Q45885040 | ||
| Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory | Q46347403 | ||
| The economy of T-cell memory: CD4+ recession in times of CD8+ stability? | Q46937082 | ||
| Bcl-2 reduces lymphomagenesis in deltaV-TCRbeta transgenic mice. | Q50950752 | ||
| Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells | Q57729519 | ||
| Expression of the Bcl-2 protein in murine and human thymocytes and in peripheral T lymphocytes | Q61716209 | ||
| Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients | Q69548004 | ||
| Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor | Q72059554 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | overexpression | Q61643320 |
| P304 | page(s) | 2001-2008 | |
| P577 | publication date | 2005-03-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Bcl-2 overexpression enhances tumor-specific T-cell survival | |
| P478 | volume | 65 |
| Q35781892 | 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines |
| Q38227889 | A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy |
| Q37365728 | Aberrant tissue localization of fungus-specific CD4+ T cells in IL-10-deficient mice |
| Q37257207 | Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology |
| Q27006934 | Adoptive T-cell therapy for Leukemia |
| Q27004178 | Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook |
| Q24546258 | Adoptive immunotherapy for cancer: building on success |
| Q28262548 | Adoptive immunotherapy for cancer: harnessing the T cell response |
| Q36293682 | Amplifying TLR-MyD88 Signals within Tumor-Specific T Cells Enhances Antitumor Activity to Suboptimal Levels of Weakly Immunogenic Tumor Antigens |
| Q89574422 | BCL-2 antagonism sensitizes cytotoxic t cell-resistant hiv reservoirs to elimination ex vivo |
| Q38205228 | Cell transfer therapy for cancer: past, present, and future |
| Q37120169 | Cell vehicle targeting strategies |
| Q47561397 | Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications |
| Q50024580 | Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity |
| Q26750908 | Chimeric antigen receptor T-cell therapy for solid tumors |
| Q27013599 | Chimeric antigen receptor therapy for cancer |
| Q40007577 | Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway |
| Q36449873 | Clinical opportunities in combining immunotherapy with radiation therapy |
| Q38631108 | Current status of chimeric antigen receptor therapy for haematological malignancies |
| Q35839860 | Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene |
| Q39277476 | Dying to protect: cell death and the control of T-cell homeostasis. |
| Q33578792 | Engineered T cells for cancer treatment |
| Q36970863 | Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas |
| Q36889204 | Enhancing adoptive T cell immunotherapy with microRNA therapeutics |
| Q37687429 | Enhancing adoptive immunotherapy of cancer. |
| Q38123667 | Gene-engineered T cells for cancer therapy |
| Q37965815 | Genetic engineering of T cells for the immunotherapy of haematological malignancies. |
| Q26995677 | Genetic engineering with T cell receptors |
| Q36909362 | Genetic modification of T cells for immunotherapy |
| Q37809463 | Harnessing the Effect of Adoptively Transferred Tumor‐Reactive T Cells on Endogenous (Host‐Derived) Antitumor Immunity |
| Q34188383 | Immunotherapy of human cancers using gene modified T lymphocytes |
| Q36407236 | Improving T cell therapy for cancer |
| Q37286334 | Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death. |
| Q30429380 | Interface of Signal Transduction Inhibition and Immunotherapy in Melanoma |
| Q52909563 | Making and circumventing tolerance to cancer. |
| Q38895203 | Multiplexed gene transfer to a human T-cell line by combining Sleeping Beauty transposon system with methotrexate selection |
| Q37372247 | Nuclear Phosphoproteomic Screen Uncovers ACLY as Mediator of IL-2-induced Proliferation of CD4+ T lymphocytes. |
| Q41588248 | Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts. |
| Q84600405 | Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein |
| Q94545391 | Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward |
| Q37001690 | Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer |
| Q46871198 | Relationship Between PD-L1 Expression and Clinical Characteristics in Patients with Breast Invasive Ductal Carcinoma |
| Q39493084 | Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes |
| Q27335748 | Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment |
| Q36328805 | Supernatural T cells: genetic modification of T cells for cancer therapy |
| Q38068003 | T cell-based gene therapy of cancer |
| Q45873576 | T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice. |
| Q36306644 | The past, present, and future of adoptive T cell therapy |
| Q26797282 | The progress of immunotherapy for glioblastoma |
| Q50045997 | Tumor antigen delivered by Salmonella III secretion protein fused with heat shock protein 70 induces protection and eradication against murine melanoma |
| Q37970674 | Tumor evasion from T cell surveillance |
| Q38217028 | Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development |
| Q35082212 | Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation |
| Q50993575 | Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors. |
Search more.